Sawai Pharmaceutical Co., Ltd.

Through this acquisition, Taiwan-based Bora not only gains additional capacity to support the generics manufacturer and CDMO business but also completes its capabilities to serve customers throughout the value chain, covering the entire US market. Bora’s board of directors announced its board of directors had approved the acquisition from shareholders Sawai Group Holdings Co., Ltd and Sumitomo Corporation of Americas on January 16. Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth and Maple Grove, Minnesota. The companies say that Upsher-Smith is highly respected in the industry and is recognized as a reliable partner with solid manufacturing capabilities, a robust distribution network, and established commercial relationships. Combined, the two manufacturing facilities in Minnesota are capable of commercializing a broad range of dosage forms including oral solids, powders (both oral and topical), and liquid, as well as packaging. Deep industry expertise Bora says Upsher-Smith’s product portfolio also presents significant opportunities for its commercial Rx business, TWi, in the US. The manufacturer’s decades-long presence in the US generics market offers deep industry expertise and know-how, as well as a well-recognized and respected name. In addition to an immediate revenue stream from a diversified portfolio of generic and branded products, Upsher-Smith will also offer TWi enhanced product development and marketing capabilities so that it can continue to broaden its suite of products and grow its US commercial business. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Bobby Sheng, chairman and CEO of Bora Group, said: “This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the US market and significantly enhancing Bora’s position as a global competitor with regard to its CDMO business and commercial Rx business. “Upsher-Smith’s competitiveness is a perfect match to Bora’s long-term growth – its newly-expanded, USFDA-approved manufacturing facilities, with a total capacity of 3.5 billion doses, will be Bora’s first local facility in the US, establishing a crucial stronghold for our global CDMO business.” “Upsher-Smith’s platform for specialty generics will strengthen TWi’s advantage in the US commercial sale business with a complementary portfolio and differentiated distribution channels. We are confident, and also committed, to delivering another successful integration for accelerating Bora’s expansion and growth in the market.” Bora's expansion into the US The closing of the transaction is subject to customary regulatory approvals. Upon closing, Bora, via its wholly-owned subsidiary in the US, will acquire 100% equity interest of Upsher-Smith. Bora says the acquisition marks its first in the US and that this signifies an expansion central to Bora’s presence in the US market and that it will create substantial opportunities for the company’s global CDMO business and commercial sales operations. The acquisition provides Bora with its first local sites dedicated to its US-based and international CDMO customers. Upsher-Smith said it has established an ‘attractive specialty generics business' in the US, introducing a complementary portfolio and sales channel to Bora’s commercial Rx business Twi.

[09-January-2024] TAMPA, Fla., Jan. 9, 2024 /PRNewswire/ -- Neurolief, a global leader in medical devices delivering groundbreaking neurotechnology innovations for the treatment of Neurological and Neuropsychiatric disorders, announces the approval of its neuromodulation device, Relivion®, by the Japanese Ministry of Health, Labor and Welfare (MHLW). This approval marks a historic moment for Neurolief and its partner Sawai Pharmaceutical Co., Ltd, as Relivion® becomes the first neuromodulation device approved in Japan for at-home use in the acute treatment of migraine. Relivion® is a novel, non-invasive multi-channel brain neuromodulation technology. It stands out by concurrently stimulating the occipital and trigeminal nerve branches in the head, effectively modulating brain networks associated with debilitating migraine headaches. The system is complemented by a state-of-the-art patient mobile app and a physician interface featuring cloud-enabled data-tracking capabilities, allowing seamless AI integration and enabling remote patient monitoring. Marketing efforts for Relivion® will be led by Sawai Pharmaceutical Co., Ltd, which have entered into an exclusive partnership agreement with Neurolief for development and commercialization of Relivion® for migraine and depression indications in Japan. Scott Drees, CEO of Neurolief, expressed great enthusiasm for the MHLW approval, emphasizing the profound impact this decision will have on the millions of migraine patients in Japan. He underscored this achievement as a pivotal step in realizing Neurolief's mission of bringing its pioneering neurotechnology to individuals globally. Motohiko Kimura, President at Sawai pharmaceutical, emphasized the company's unwavering dedication to prioritizing patients through Sawai's corporate philosophy of 'Always Putting Patients First'. This commitment reflects Sawai's strong resolve to contribute to healthier lives. With the upcoming introduction of the Relivion® neuromodulation system in Japan, Sawai aims to elevate the landscape of acute migraine treatment options which is currently limited primarily to drug therapy. About Neurolief Neurolief is a leading brain neurotechnology company dedicated to enhancing the lives of patients suffering from Neurological and Neuropsychiatric disorders. Comprising experienced professionals with a proven track record in neuroscience, neuromodulation technology and the neurotech devices industry, the company has developed Relivion®MG for the treatment of migraine and Relivion®DP for Major Depressive Disorder (MDD). These are the world's first and only non-invasive multi-channel brain neuromodulation technologies designed to concurrently stimulate the occipital and trigeminal nerve branches in the head, thereby modulating brain networks associated with migraine and depression. Relivion®MG is currently FDA, CE and MHLW approved for the acute treatment of migraine and aims to provide a highly effective alternative to pharmaceutical therapies. The system also includes a patient mobile app and a physicians' interface with cloud-enabled data-tracking features, enabling AI incorporation and remote patient monitoring. The company is actively pursuing FDA and CE mark approvals for the treatment of Major Depressive Disorder (MDD). For additional information on Neurolief and Relivion®, please visit our website at

MAPLE GROVE, Minn. , Nov. 6, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Pitavastatin Tablets in 1 mg, 2 mg, and 4 mg strengths. The Pitavastatin Tablet market had U.S. sales of approximately $302 million for the 12 months ending August 2023 according to IQVIA. Pitavastatin Tablets are an AB-rated, generic equivalent to the brand product, LIVALO® (pitavastatin) tablets.* Continue Reading Pitavastatin Tablets in 1 mg, 2 mg, and 4 mg strengths. Upsher-Smith Laboratories, LLC Sawai Group Holdings Co., Ltd.'s (Sawai) company, Sawai USA, Inc. holds the ANDA for Pitavastatin tablets. This marks Sawai's first Paragraph IV product to be launched in the United States market. Upsher-Smith will distribute the product in the U.S. Product Information For questions about ordering, please call Upsher-Smith at 1-800-654-2299. Please refer to the full Prescribing Information for Pitavastatin Tablets here . You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information . You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting . About Upsher-Smith Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings generics and brands to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit . *LIVALO is a registered trademark of the Kowa group of companies. SOURCE Upsher-Smith Laboratories, LLC